Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Browsing Tag

Lunsumio

5 posts
RRoche
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Read More

Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas

  • 2026-03-03
F. Hoffmann-La Roche Ltd Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory…
RRoche
Roche fenebrutinib Phase III hits PPMS disability goal
Read More

Roche: Lunsumio combo hits 87.0% CR in follicular lymphoma

  • 2026-02-21
Roche (OTCQX: RHHBY) presented data at ASH 2025 showing Lunsumio (mosunetuzumab) combinations may…
RRoche
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
Read More

European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma

  • 2026-02-18
F. Hoffmann-La Roche Ltd Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular…
RRoche
Roche fenebrutinib Phase III hits PPMS disability goal
Read More

Roche to Present 46 Abstracts, 12 Orals at ASH Meeting

  • 2026-02-17
Roche (OTCQX: RHHBY) will present 46 abstracts, including 12 oral presentations, at ASH…
RRoche
Roche fenebrutinib Phase III hits PPMS disability goal
Read More

Roche Receives Conditional Authorisation for Lunsumio SC

  • 2026-02-16
Roche (OTCQX: RHHBY) announced the European Commission granted conditional marketing authorisation for Lunsumio…
Switzerland
www.europesays.com